Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
April 25, 2023
Much ink has been spilled over the impact of borrowing country institutions and the policies and practices of donor organizations on aid effectiveness. But what do we know about the role of those individuals who often represent the key interface between country-level institutions and donor-funded pr...
Blog Post
April 24, 2023
As World Immunization Week kicks off today, childhood vaccination remains among the most cost-effective uses of health spending. Significant progress has been made to expand global vaccine coverage. Yet, rates remain inequitable and highly variable—within countries but also across those in the same ...
Blog Post
March 07, 2023
The EU and its member states are collectively the world’s largest aid donor, with an annual budget of over $70 billion in 2021. When it comes to global health, however, it has historically punched below its weight. In part, this is due to an internal coordination problem; health is a shared competen...
Blog Post
February 10, 2023
Although African governments that deliver higher rates of primary enrollment enjoy greater approval ratings, the relative importance of access is likely to decline as countries approach universal primary education. That is already reflected in the prominence of learning outcomes as a predictor of ci...
Blog Post
January 25, 2023
Last month, the Center for Global Development (CGD), the White House Office of Science and Technology Policy, and the Office of Management and Budget co-hosted an Evidence Forum as part of the White House Year of Evidence for Action, featuring USAID Administer Samantha Power. The event celebrated pr...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.